$181 Million is the total value of VHCP Management, LLC's 18 reported holdings in Q3 2013. The portfolio turnover from Q2 2013 to Q3 2013 was 29.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DYAX | Dyax Corp | $28,514,000 | +98.3% | 4,156,508 | 0.0% | 15.75% | +47.4% | |
| IRWD | Ironwood Pharmaceuticals Inc | $21,312,000 | +19.2% | 1,800,000 | 0.0% | 11.77% | -11.3% | |
| KERX | Keryx Biopharmaceuticals Inc | $20,672,000 | +35.1% | 2,048,773 | 0.0% | 11.42% | +0.4% | |
| ANAC | Anacor Pharmaceuticals Inc | $17,107,000 | +90.0% | 1,610,856 | 0.0% | 9.45% | +41.3% | |
| BCRX | Buy | BioCryst Pharmaceuticals Inc | $15,875,000 | +910.5% | 2,180,656 | +115.2% | 8.77% | +651.2% |
| GWPH | GW Pharmaceuticals | $14,527,000 | +96.8% | 837,800 | 0.0% | 8.02% | +46.4% | |
| NBIX | Sell | Neurocrine Biosciences Inc | $14,391,000 | -45.3% | 1,271,303 | -35.3% | 7.95% | -59.3% |
| TSRO | TESARO Inc | $10,116,000 | +18.3% | 261,130 | 0.0% | 5.59% | -12.0% | |
| CHTP | Chelsea Therapeutics International Ltd | $7,525,000 | +30.0% | 2,516,870 | 0.0% | 4.16% | -3.3% | |
| HPTX | Sell | Hyperion Therapeutics Inc | $5,685,000 | +1.3% | 217,571 | -14.7% | 3.14% | -24.6% |
| VNDA | Sell | Vanda Pharmaceuticals Inc | $5,377,000 | -15.5% | 491,075 | -37.6% | 2.97% | -37.1% |
| New | DBV Technologies | $5,094,000 | – | 480,000 | +100.0% | 2.81% | – | |
| BIOD | Sell | Biodel Inc | $4,037,000 | -33.2% | 1,281,592 | -11.4% | 2.23% | -50.4% |
| THLD | Threshold Pharmaceuticals Inc | $3,181,000 | -11.6% | 684,000 | 0.0% | 1.76% | -34.2% | |
| APPA | New | A P Pharma Inc | $3,038,000 | – | 9,067,700 | +100.0% | 1.68% | – |
| ALXA | Alexza Pharmaceuticals Inc | $2,048,000 | +18.0% | 399,999 | 0.0% | 1.13% | -12.3% | |
| OPHT | New | Ophthotech Corporation | $1,560,000 | – | 52,500 | +100.0% | 0.86% | – |
| GTXI | GTx Inc | $1,013,000 | -69.3% | 500,000 | 0.0% | 0.56% | -77.2% | |
| ANTH | Exit | Anthera Pharmaceuticals Inc | $0 | – | -1,437,623 | -100.0% | -0.50% | – |
| STML | Exit | Stemline Therapeutics Inc | $0 | – | -50,000 | -100.0% | -0.88% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DBV Technologies | 14 | Q4 2016 | 33.5% |
| BioCryst Pharmaceuticals Inc | 13 | Q4 2016 | 11.9% |
| Ocera Therapeutics | 13 | Q4 2016 | 4.9% |
| Anacor Pharmaceuticals Inc | 12 | Q1 2016 | 35.6% |
| Heron Therapeutics Inc | 12 | Q4 2016 | 20.5% |
| Flamel Technologies S.A. | 12 | Q4 2016 | 6.1% |
| GW Pharmaceuticals | 11 | Q4 2015 | 19.9% |
| Lipocine Inc | 11 | Q4 2016 | 7.5% |
| Stemline Therapeutics Inc | 11 | Q4 2016 | 1.7% |
| Zafgen Inc | 10 | Q3 2016 | 5.7% |
View VHCP Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2018-02-28 |
| 13F-HR | 2017-02-13 |
| 13F-HR | 2016-11-14 |
| 13F-HR | 2016-08-12 |
| 13F-HR | 2016-05-13 |
| 13F-HR | 2016-02-12 |
| 13F-HR | 2015-11-13 |
| 13F-HR | 2015-08-13 |
| 3 | 2015-06-17 |
| 13F-HR | 2015-05-14 |
View VHCP Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.